Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All bromhexine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2

Habtemariam et al., Pharmacol. Res., doi:10.1016/j.phrs.2020.104853
Apr 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Note on the potential use of bromhexine hydrochloride for prophylaxis of SARS-CoV-2, based on the role of TMPRSS2 in SARS-CoV-2 infection, and the TMPRSS2 inhibition of bromhexine hydrochloride.
Habtemariam et al., 30 Apr 2020, peer-reviewed, 6 authors.
This PaperBromhexineAll
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Solomon Habtemariam Pharmacognosy Research Laboratories and Herbal Analysis
References
Hoffmann, Kleine-Weber, Schroeder, Krüger, Herrler et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Iwata-Yoshikawa, Okamura, Shimizu, Hasegawa, Takeda et al., TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection, J. Virol
Limburg, Harbig, Bestle, Stein, Moulton et al., TMPRSS2 is the major activating protease of influenza A virus in primary human airway cells and influenza B virus in human type II pneumocytes, J. Virol
Lukassen, Chua, Trefzer, Kahn, Schneider et al., SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells, EMBO J, doi:10.15252/embj.2020105114
Matsuyama, Nao, Shirato, Kawase, Saito et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, Proc. Natl. Acad. Sci, doi:10.1073/pnas.2002589117
Shen, Mao, Wu, Tanaka, Zhang, TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections, Biochimie
Zmora, Hoffmann, Kollmus, Moldenhauer, Danov et al., TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1, J. Biol. Chem
{ 'indexed': {'date-parts': [[2024, 3, 19]], 'date-time': '2024-03-19T12:27:45Z', 'timestamp': 1710851265320}, 'reference-count': 7, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2020, 7, 1]], 'date-time': '2020-07-01T00:00:00Z', 'timestamp': 1593561600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 7]]}, 'DOI': '10.1016/j.phrs.2020.104853', 'type': 'journal-article', 'created': {'date-parts': [[2020, 4, 30]], 'date-time': '2020-04-30T17:12:44Z', 'timestamp': 1588266764000}, 'page': '104853', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 30, 'title': 'Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against ' 'SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2', 'prefix': '10.1016', 'volume': '157', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-6743-2244', 'authenticated-orcid': False, 'given': 'Solomon', 'family': 'Habtemariam', 'sequence': 'first', 'affiliation': []}, {'given': 'Seyed Fazel', 'family': 'Nabavi', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5948-508X', 'authenticated-orcid': False, 'given': 'Saeid', 'family': 'Ghavami', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5716-8101', 'authenticated-orcid': False, 'given': 'Cosmin Andrei', 'family': 'Cismaru', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ioana', 'family': 'Berindan-Neagoe', 'sequence': 'additional', 'affiliation': []}, {'given': 'Seyed Mohammad', 'family': 'Nabavi', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.phrs.2020.104853_bib0005', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1016/j.biochi.2017.07.016', 'article-title': 'TMPRSS2: a potential target for treatment of influenza virus and ' 'coronavirus infections', 'volume': '142', 'author': 'Shen', 'year': '2017', 'journal-title': 'Biochimie'}, { 'key': '10.1016/j.phrs.2020.104853_bib0010', 'doi-asserted-by': 'crossref', 'first-page': 'e01815', 'DOI': '10.1128/JVI.01815-18', 'article-title': 'TMPRSS2 contributes to virus spread and immunopathology in the airways ' 'of murine models after coronavirus infection', 'volume': '93', 'author': 'Iwata-Yoshikawa', 'year': '2019', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.phrs.2020.104853_bib0015', 'doi-asserted-by': 'crossref', 'DOI': '10.1073/pnas.2002589117', 'article-title': 'Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells', 'author': 'Matsuyama', 'year': '2020', 'journal-title': 'Proc. Natl. Acad. Sci. U. S. A.'}, { 'key': '10.1016/j.phrs.2020.104853_bib0020', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'author': 'Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'key': '10.1016/j.phrs.2020.104853_bib0025', 'doi-asserted-by': 'crossref', 'DOI': '10.15252/embj.20105114', 'article-title': 'SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in ' 'bronchial transient secretory cells', 'author': 'Lukassen', 'year': '2020', 'journal-title': 'EMBO J.'}, { 'key': '10.1016/j.phrs.2020.104853_bib0030', 'doi-asserted-by': 'crossref', 'first-page': '13863', 'DOI': '10.1074/jbc.RA118.001273', 'article-title': 'TMPRSS11A activates the influenza A virus hemagglutinin and the MERS ' 'coronavirus spike protein and is insensitive against blockade by HAI-1', 'volume': '293', 'author': 'Zmora', 'year': '2018', 'journal-title': 'J. Biol. Chem.'}, { 'key': '10.1016/j.phrs.2020.104853_bib0035', 'doi-asserted-by': 'crossref', 'first-page': 'e00649', 'DOI': '10.1128/JVI.00649-19', 'article-title': 'TMPRSS2 is the major activating protease of influenza A virus in ' 'primary human airway cells and influenza B virus in human type II ' 'pneumocytes', 'volume': '93', 'author': 'Limburg', 'year': '2019', 'journal-title': 'J. Virol.'}], 'container-title': 'Pharmacological Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1043661820311610?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1043661820311610?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 12, 4]], 'date-time': '2020-12-04T23:56:37Z', 'timestamp': 1607126197000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1043661820311610'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 7]]}, 'references-count': 7, 'alternative-id': ['S1043661820311610'], 'URL': 'http://dx.doi.org/10.1016/j.phrs.2020.104853', 'relation': {}, 'ISSN': ['1043-6618'], 'subject': [], 'container-title-short': 'Pharmacological Research', 'published': {'date-parts': [[2020, 7]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic ' 'agent against SARS-CoV-2 infection based on its action on the Transmembrane ' 'Serine Protease 2', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Pharmacological Research', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.phrs.2020.104853', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '104853'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit